ReviewDrug design, development and therapy2022

Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis.

Edgar Carnero Contentti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.